- WORLD EDITIONAustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
GeoVax Labs announced the publication of a new scientific paper detailing the latest on the company’s efforts against Zika.
GeoVax Labs (OTCQB:GOVX) announced the publication of a new scientific paper detailing the latest on the company’s efforts against Zika.
As quoted in the press release:
The paper published today reports research showing that a single intramuscular dose of GeoVax’s Zika vaccine (GEO-ZM02) provided 100% protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is i) the only Zika vaccine in development which is based solely on the ZIKV NS1 protein, and ii) the first report of single-dose vaccine that afforded full protection against ZIKV using an immunocompetent lethal mouse challenge model.
The vaccine was tested at the Division of Vector-Borne Diseases, Centers for Disease Control and Prevention (CDC) in Fort Collins, Colorado with funding from the CDC. In the study, outbred immunocompetent mice were exposed to a lethal challenge dose of ZIKV delivered directly into the brain. A single dose of GeoVax’s ZIKV NS1 vaccine protected 100% of vaccinated animals. In contrast, 80-90% of sham-immunized control animals died within ~7 days.
Click here to read the full press release.
Source: www.marketwired.com
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.